A Phase II Study in Adult Patients With Moderate to Severe Atopic Dermatitis

The requested reference [ccf04e2c3ae4075c5e211982218f8e7e48414788] no longer exists in our database. It has been replaced by the current reference: [1ab91e828b29dd031ca74299f2aafb7584bdef63]

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2019
This proposed study is a randomized, double-blind, placebo-controlled, 3-arm parallel, multicenter phase II study, designed to explore the efficacy and safety of SHR0302 treatment for patients with moderate to severe atopic dermatitis. The study will be conducted over a 12-week treatment period. Two active doses of SHR0302 will be compared to placebo and improvement in atopic dermatitis will be assessed using the Investigator\'s Global Score (IGA)
Epistemonikos ID: 8b71e60771bc1a9b3eac6aeed1cfe4234199132d
First added on: May 06, 2024